Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Aringer

Showing results (161-170 of 217) with videos related to

Pageof 22
Sort By:
Arthritis and Rheumatism|April 29, 2008
Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical featuresEsther Jimenez-Boj, Nancy Kedersha, Makiyeh Tohidast-Akrad, et al.
Lupus Science & Medicine|December 20, 2023
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signatureLaurent Arnaud, Richard Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|June 24, 2021
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patientsKaterina Chavatza, Myrto Kostopoulou, Dionysis Nikolopoulos, et al.
Zeitschrift Fur Rheumatologie|April 3, 2024
[Current data on rheumatological care: annual report from the National database (NDB) of the regional collaborative arthritis centres in Germany]Katinka Albrecht, Katja Thiele, Tobias Alexander, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
The New England Journal of Medicine|July 27, 2017
Trial of Tocilizumab in Giant-Cell ArteritisJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Zeitschrift Fur Rheumatologie|May 5, 2025
[Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany]Katinka Albrecht, Katja Thiele, Tobias Alexander, et al.
Arthritis Care & Research|July 11, 2017
Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International CollaborationSara K Tedeschi, Sindhu R Johnson, Dimitrios Boumpas, et al.
Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
Pageof 22

Showing results (161-170 of 217) with videos related to

Sort By:
Pageof 22
Arthritis and Rheumatism|April 29, 2008
Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical featuresEsther Jimenez-Boj, Nancy Kedersha, Makiyeh Tohidast-Akrad, et al.
Lupus Science & Medicine|December 20, 2023
Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signatureLaurent Arnaud, Richard Furie, Eric F Morand, et al.
Annals of the Rheumatic Diseases|June 24, 2021
Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patientsKaterina Chavatza, Myrto Kostopoulou, Dionysis Nikolopoulos, et al.
Zeitschrift Fur Rheumatologie|April 3, 2024
[Current data on rheumatological care: annual report from the National database (NDB) of the regional collaborative arthritis centres in Germany]Katinka Albrecht, Katja Thiele, Tobias Alexander, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 6, 2019
Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of TocilizumabJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.
The New England Journal of Medicine|July 27, 2017
Trial of Tocilizumab in Giant-Cell ArteritisJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.
Zeitschrift Fur Rheumatologie|May 5, 2025
[Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany]Katinka Albrecht, Katja Thiele, Tobias Alexander, et al.
Arthritis Care & Research|July 11, 2017
Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International CollaborationSara K Tedeschi, Sindhu R Johnson, Dimitrios Boumpas, et al.
Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.
Pageof 22